ReviewMicroorganisms2022
Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 109 citations in OpenAlex.
- Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics.International journal of molecular sciences · 2026Review
- Molecular Regulation of Biofilm Development inPathogens (Basel, Switzerland) · 2026Review
- Inhibition and disruption of bacterial biofilms by a bipyridine-ruthenium complex: a broad-spectrum in vitro study.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Review
- Plant-Derived Peptide-Polymer Therapeutics for Cutaneous Infections and Inflammation: Mechanistic Basis, Delivery Design and Translational Considerations.Pharmaceutics · 2026Review
- Lactic Acid Bacteria-derived Bacteriocins: A Promising Antimicrobial Strategy against Multidrug-resistant for Neonatal Sepsis Pathogens.Probiotics and antimicrobial proteins · 2026Review
- Tunable anti-biofilm activity of Zn-doped CuO nanoparticles: structural, morphological, and biological insights against Gram-positive and Gram-negative bacteria.RSC advances · 2026Article
- Green-synthesized silver nanoparticles againstMaterials today. Bio · 2026Article
- Mechanisms of Bacterial Resistance and Innovative Strategies to Overcome Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- EthanolicMicroorganisms · 2026Article
- Antimicrobial Peptides as Next-Generation Disinfectants: Tackling Biocide and Antimicrobial Resistance in Hospital Hygiene - A Narrative Review.Probiotics and antimicrobial proteins · 2026Review
- Appraisal of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- A green approach for synthesizing zinc oxide nanoparticles utilizing aqueous extract of lemon peel: antibacterial evaluation and in silico analysis.Frontiers in chemistry · 2026Article
- Emerging Multimodal Strategies for Bacterial Biofilm Eradication: A Comprehensive Review.Microorganisms · 2025Review
- Domain antibody-displayed phages as a novel biofilm-targeted therapy for Staphylococcus aureus.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- GC-MS characterization of bioactive compounds from Lippia multiflora Moldenke (Verbenaceae) flower essential oils and their antibiofilm potential against resistant bacteria.Scientific reports · 2025Article
- Effect of 1,3,4-oxadiazoles on expression of biofilm-associated bap gene in clinical isolates of multidrug-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Antibacterial and antibiofilm activity of nanoparticles inRSC advances · 2025Article
- Modulating Antimicrobial Activity and Structure of the Peptide Esc(1-21) via Site-Specific Isopeptide Bond Formation.Journal of peptide science : an official publication of the European Peptide Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A biofilm is a community of stable microorganisms encapsulated in an extracellular matrix produced by themselves. Many types of microorganisms that are found on living hosts or in the environment can form biofilms. These include pathogenic bacteria that can serve as a reservoir for persistent infections, and are culpable for leading to a broad spectrum of chronic illnesses and emergence of antibiotic resistance making them difficult to be treated. The absence of biofilm-targeting antibiotics in the drug discovery pipeline indicates an unmet opportunity for designing new biofilm inhibitors as antimicrobial agents using various strategies and targeting distinct stages of biofilm formation. The strategies available to control biofilm formation include targeting the enzymes and proteins specific to the microorganism and those involved in the adhesion pathways leading to formation of resistant biofilms. This review primarily focuses on the recent strategies and advances responsible for identifying a myriad of antibiofilm agents and their mechanism of biofilm inhibition, including extracellular polymeric substance synthesis inhibitors, adhesion inhibitors, quorum sensing inhibitors, efflux pump inhibitors, and cyclic diguanylate inhibitors. Furthermore, we present the structure-activity relationships (SAR) of these agents, including recently discovered biofilm inhibitors, nature-derived bioactive scaffolds, synthetic small molecules, antimicrobial peptides, bioactive compounds isolated from fungi, non-proteinogenic amino acids and antibiotics. We hope to fuel interest and focus research efforts on the development of agents targeting the uniquely complex, physical and chemical heterogeneous biofilms through a multipronged approach and combinatorial therapeutics for a more effective control and management of biofilms across diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.